Archives: Research

Research & Insights Content Type

  • Xeljanz, the FDA, and nine years of patient harm

  • Atypical antipsychotics: Decades of use, unfathomable harms

  • Medicare Part B Premium Dynamics Explained

  • Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Evaluating Industry’s Drug Pricing Claims

  • Mapping conflict of interests: scoping review

  • Production Plus Profit Pricing (P-quad) FAQ

  • What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs

  • Medicare Must Study Unproven, Expensive Alzheimer’s Drug